Contains Nonbinding Recommendations

Draft Guidance on Alprazolam

This draft guidance, once finalized, will represent the Food and Drug Administration's (FDA's) current thinking on this topic. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. You can use an alternative approach if the approach satisfies the requirements of the applicable statutes and regulations. If you want to discuss an alternative approach, contact the Office of Generic Drugs.

Active ingredient: Alprazolam

Form/Route: Orally Disintegrating Tablet/Oral

Recommended studies: 2 studies

  Type of study: Fasting
  Design: Single-dose, two-treatment, two-period crossover in-vivo
  Strength: 1 mg
  Subjects: Normal healthy males and females, general population
  Additional Comments: The whole tablet should be placed on the tongue and allowed to disintegrate for 30 seconds. After 30 seconds, all subjects should consume 240 mL of water.

  Type of study: Fed
  Design: Single-dose, two-treatment, two-period crossover in-vivo
  Strength: 1 mg
  Subjects: Normal healthy males and females, general population
  Additional Comments: See comments above

Analytes to measure: Alprazolam in plasma

Bioequivalence based on (90% CI): Alprazolam

Waiver request of in-vivo testing: 0.25 mg, 0.5 mg and 2 mg based on (i) acceptable bioequivalence studies on the 1 mg strength, (ii) proportional similarity of the formulations across all strengths, and (iii) acceptable in vitro dissolution testing of all strengths.

Dissolution test method and sampling times:

Please note that a Dissolution Methods Database is available to the public at the OGD website at http://www.fda.gov/cder/ogd/index.htm. Please find the dissolution information for this product at this website. Please conduct comparative dissolution testing on 12 dosage units each of all strengths of the test and reference products. Specifications will be determined upon review of the application.

Recommended Sep 2008